Metabolic Syndrome And Jak Inibitors: Current Status And Perspective
Medical - Clinical - Research · 2025
DOI: 10.52106/3069-9088.1001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical - Clinical - Research, 2025. Verfasst von Carmine Finelli und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Obesity is a major risk factor for metabolic syndrome (MetS), a cluster of metabolic disorders including hepatic steatosis, hyperglycemia, hyperlipidemia, and hyperinsulinemia. Chronic low-grade inflammation (CLGI), particularly in adipose and hepatic tissues, plays a key role in the onset of MetS, with Toll-like receptors (TLRs) and cytokine signaling pathways such as NF-κB activation being central mediators. Recent studies highlight the involvement of the gastrointestinal (GI) tract and mucosal immunity, particularly the role of Janus kinase 3 (Jak3), in regulating gut inflammation and barrier functions. Loss of Jak3 expression in the colonic mucosa is associated with increased susceptibility to obesity and CLGI, suggesting a potential role in the pathogenesis of MetS and related diabetes. However, the specific mechanisms by which Jak3 contributes to these processes remain to be fully elucidated.
Zitieren
APA
Finelli, C., & Sasso, S. D. (2025). Metabolic Syndrome And Jak Inibitors: Current Status And Perspective. Medical - Clinical - Research. https://doi.org/10.52106/3069-9088.1001
Vancouver
Finelli C, Sasso SD. Metabolic Syndrome And Jak Inibitors: Current Status And Perspective. Medical - Clinical - Research. 2025. doi:10.52106/3069-9088.1001
BibTeX
@article{Finelli2025,
author = {Finelli, Carmine and Sasso, Simone Dal},
title = {Metabolic Syndrome And Jak Inibitors: Current Status And Perspective},
journal = {Medical - Clinical - Research},
year = {2025},
doi = {10.52106/3069-9088.1001}
}
EUVIMED